Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cancer Survival Analysis01:21

Cancer Survival Analysis

402
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
402

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.

Blood cancer discovery·2026
Same author

Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Blood·2026
Same author

Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor-Resistant Chronic Lymphocytic Leukemia.

Blood cancer discovery·2025
Same author

A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases.

Journal of comparative effectiveness research·2025

相关实验视频

Updated: Jul 27, 2025

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.8K

对高风险的CLLL进行引人入胜的分析

Kerry A Rogers

    Clinical cancer research : an official journal of the American Association for Cancer Research
    |June 8, 2023
    PubMed
    概括

    以前未经治疗的患有较高风险特征的慢性淋巴细胞白血病患者,与未接受治疗的患者相比,在ibrutinib和venetoclax治疗时表现相似. 这种固定时间的治疗提供了可比的疗效和安全性,无论遗传标记.

    科学领域:

    • 血液学 血液学 血液学
    • 在瘤学瘤学.
    • 临床试验 临床试验

    背景情况:

    • 慢性淋巴细胞白血病 (CLL) 是一种常见的淋巴细胞恶性瘤.
    • 某些基因突变,如IGHV未变异状态,del(17p) 和TP53突变,定义了更高风险的CLL.
    • 对CLL的标准治疗方法因风险分层而有所不同.

    研究的目的:

    • 在以前未经治疗的CLL患者中探索固定的时间内布鲁替尼和维尼托克拉克斯的疗效和安全性.
    • 为了比较具有或没有高风险遗传特征的CLL患者之间的结果.

    主要方法:

    • 第二阶段CAPTIVATE研究的探索性分析.
    • 用固定持续时间的易布鲁替尼和维内托克拉克斯治疗.
    • 基于IGHV未变异状态,del ((17p) 和/或TP53突变的患者分层.

    主要成果:

    • 患有较高风险的CLL特征的患者表现出与没有这些特征的患者相似的疗效结果.
    • 高风险和低风险患者群体之间的安全概况相似.
    • 固定的持续时间的易布鲁替尼和维尼托克拉克斯在风险层中显示出一致的结果.

    结论:

    更多相关视频

    Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
    09:02

    Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

    Published on: November 26, 2018

    21.2K
    HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
    11:29

    HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

    Published on: July 20, 2016

    11.1K

    相关实验视频

    Last Updated: Jul 27, 2025

    From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
    10:18

    From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

    Published on: October 19, 2014

    13.8K
    Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
    09:02

    Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

    Published on: November 26, 2018

    21.2K
    HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
    11:29

    HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

    Published on: July 20, 2016

    11.1K
    • 固定持续时间的易布鲁替尼和威尼托克拉克斯是以前未经治疗的CLL患者的有效治疗选择,无论高风险的遗传标记是什么.
    • 组合疗法在患有或没有del 17p,TP53突变或IGHV未变异状态的患者中提供了相似的疗效和安全性.
    • 这些发现支持在更广泛的CLL群体中使用这种治疗方案.